Skip to main content

Featured

Bank of Canada Holds at 2.25% — Again: What It Means for Your Mortgage and Markets Today

  Wednesday, June 10, 2026  |  Canadian Money Brief It's official: the Bank of Canada held its overnight rate steady at 2.25% this morning — the fourth consecutive hold in 2026 , following identical decisions in January, March, and April. The move was widely anticipated, but the language in today's statement and Governor Tiff Macklem's 10:30 a.m. press conference are delivering the real signal: the BoC is watching the Middle East conflict carefully, is not yet alarmed by inflation, but is making clear that rate hikes remain on the table if energy prices push inflation higher. Here's the full picture — BoC reaction, Canadian markets, Wall Street, oil, and global moves. 🏦 Bank of Canada: Holds at 2.25% — But With a Warning The Bank of Canada's statement this morning was brief but pointed. The Governing Council noted that "economic activity in Canada has been weak and uncertainty about US trade policy persists," while also flagging that "the conflict ...
Post a Comment
Read more

article

Labels

A New Dawn in Alzheimer’s Prevention: The AHEAD 3-45 Study


The AHEAD 3-45 study represents a beacon of hope for individuals like Tyson Haller, who, at 60, is determined to understand and possibly prevent the onset of Alzheimer’s—a disease that claimed his father. This groundbreaking clinical trial is testing lecanemab, an FDA-approved drug that has shown promise in slowing Alzheimer’s progression in its early stages. The optimism surrounding this trial is palpable, as it could herald a new era where Alzheimer’s is as manageable as Type 2 diabetes.

  • Family History’s Weight: Haller’s participation is driven by his family’s battle with Alzheimer’s, highlighting the emotional and proactive steps taken by those at risk.
  • Lecanemab’s Potential: The trial’s focus on lecanemab, a drug targeting beta amyloid plaques in the brain, offers a glimpse into a future where early intervention could significantly slow the disease’s impact.
  • Scientific Debate: Despite the excitement, there’s a scientific debate about beta amyloid’s role in Alzheimer’s, underscoring the complexity of finding a definitive treatment.
  • Awaiting Results: With the AHEAD and TRAILBLAZER prevention trials running until 2027 and 2029, patients, doctors, and researchers are in a state of limbo, hopeful yet uncertain of the long-term outcomes.

This study not only represents a potential turning point in Alzheimer’s research but also embodies the personal stories of those fighting to preserve their memories and identities against this relentless disease.

Labels:

Comments

Post a Comment